BerGenBio completes IPO, raising $49M for cancer trials
Norwegian clinical-stage biopharmaceutical company BerGenBio has recently completed its IPO, selling 16 million shares to hit its target price and raise $49M. The capital raised will be used to continue developing their range of selective AXL kinase inhibitors for the treatment of multiple aggressive cancers. Current programmes include phase 2 trials of their small-molecule Axl inhibitor, BGB324, and expansion their clinical-phase pipeline, with Anti-Axl antibody BGB149 set to transition into the clinic and come through a phase 1 trial.
Read the full story here.
Mewburn Ellis partner Robert Andrews works closely with BerGenBio in relation to the building and defending of their IP portfolio.